On March 16, 2021, Solid Biosciences joined PPMD for a webinar to provide a safety and efficacy update on the ongoing IGNITE DMD phase I/II clinical study of SGT-001 microdystrophin gene therapy in patients with Duchenne muscular dystrophy. Research & Clinical Trial Webinars,Webinars 4 years ago You may also like 47:28 Community Update Call: Sarepta & Summit (October 2016) 8 years ago Research & Clinical Trial Webinars,Webinars 47:33 SareptAssist Patient Services Overview (September 2016) 8 years ago Research & Clinical Trial Webinars,Webinars 1:24:01 PTC Therapeutics Provides Regulatory Update on Translarna (August 2016) 8 years ago Research & Clinical Trial Webinars,Webinars 1:00:59 What is CRISPR/Cas9? (July 2016) 8 years ago Research & Clinical Trial Webinars,Webinars gene therapy 43:52 MoveDMD: A Clinical Trial of Edasalonexent (CAT-1004) in Duchenne (June 2016) 8 years ago Research & Clinical Trial Webinars,Webinars 43:48 MissionDMD: FibroGen’s Anti-Fibrosis Program (May 2016) 8 years ago Research & Clinical Trial Webinars,Webinars 53:38 BMS Anti-Myostatin Adnectin Program (March 2016) 9 years ago Research & Clinical Trial Webinars,Webinars 1:13:48 HOPE-Duchenne Trial – Capricor Therapeutics (January 2016) 9 years ago Research & Clinical Trial Webinars,Webinars «1…1819202122…25»Page 20 of 25
by: Parent Project Muscular Dystrophy
